Daiichi Sankyo (TSE: 4568) announced plans to share extensive clinical research from its oncology portfolio at the 2024 ESMO Asia Congress (#ESMOAsia24), San Antonio Breast Cancer Symposium (#SABCS24), and American Society of Hematology (#ASH24) Annual Meeting. More than 45 abstracts, spanning multiple solid and blood cancers, will be presented ahead of the company’s annual Science & Technology Day.

Key presentations include three late-breaking studies from Daiichi Sankyo’s DXd ADC portfolio, focusing on difficult-to-treat cancers such as lung and breast. These include:

• A pooled analysis of the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials of datopotamab deruxtecan (Dato-DXd) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) at ESMO Asia.
• Subgroup analysis of the DESTINY-Breast06 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in patients with HR-positive, HER2-low or HER2-ultralow breast cancer at SABCS.
• Primary analysis of the VALENTINE phase 2 trial of patritumab deruxtecan (HER3-DXd) in patients with high-risk early-stage HR-positive, HER2-negative breast cancer at SABCS.

“These data represent significant progress in our commitment to addressing unmet needs in oncology,” said Dr. Ken Takeshita, Global Head of R&D at Daiichi Sankyo. “Our research reflects our goal of creating new standards of care for patients with cancer worldwide, particularly in challenging-to-treat cancers such as lung, breast, gastric, and blood cancers.”

Highlights at ESMO Asia

Late-breaking data at ESMO Asia will feature a pooled analysis of datopotamab deruxtecan’s efficacy and safety in EGFR-mutated advanced NSCLC from the TROPION-Lung trials. Additional presentations include:

• Results from the TROPION-Breast01 trial of datopotamab deruxtecan in Chinese patients with HR-positive, HER2-low, or HER2-negative breast cancer.
• Final analysis of DESTINY-Gastric06 evaluating ENHERTU in Chinese patients with HER2-positive gastric or gastroesophageal adenocarcinoma, which supported the drug's conditional approval in China.

Advances in Breast Cancer at SABCS

At SABCS, late-breaking presentations will showcase subgroup analyses from DESTINY-Breast06 and primary results from the VALENTINE trial, emphasizing progress in treating HR-positive, HER2-low and HER2-ultralow breast cancer. Additional data will explore:

• Biomarker analyses comparing ENHERTU with ado-trastuzumab emtansine (T-DM1).
• Health-related quality of life outcomes in patients with brain metastases treated with ENHERTU.
• Final results from the DESTINY-Breast08 trial combining ENHERTU with capecitabine or capivasertib.

Hematology Updates at ASH

Daiichi Sankyo’s hematology portfolio will be featured in several presentations, including new analyses from the QuANTUM-First trial of VANFLYTA® (quizartinib) for FLT3-ITD positive acute myeloid leukemia (AML). Data will also be shared from the QUIWI phase 2 trial of quizartinib in FLT3-ITD negative AML and the VALENTINE-PTCL01 trial of valemetostat in peripheral T-cell lymphoma.

Science & Technology Day

On December 16, Daiichi Sankyo will host its annual Science & Technology Day, offering an overview of oncology research presented at these conferences and updates on its R&D strategy.